Alterity Therapeutics enacts 1-for-50 share consolidation

Alterity Therapeutics Limited is implementing a 1 for 50 consolidation of its share capital following shareholder approval at an Extraordinary General Meeting on 29 May 2026.

Rhea-AI Filing Summary

Alterity Therapeutics Limited is implementing a 1 for 50 consolidation of its share capital following shareholder approval at an Extraordinary General Meeting on 29 May 2026. This reduces each holder’s number of shares, with fractional entitlements rounded up to at least one security and the share price adjusted accordingly.

From 3 June to the close of trading on 11 June 2026, Alterity securities trade on the ASX on a post-consolidation, deferred settlement basis under temporary code “ATHDA”, with a record date of 4 June 2026. Listed options “ATHO” and “ATHOA” temporarily trade as “ATHDB” and “ATHDC”. Normal T+2 trading under the “ATH” code resumes on 12 June 2026.

Insights

Capital markets analyst

Alterity is executing a 1-for-50 reverse split with temporary ASX codes.

Alterity Therapeutics is consolidating its share capital on a 1 for 50 basis, a mechanical change that reduces the number of shares while increasing the per-share price proportionally. Fractional holdings are rounded up to ensure each shareholder retains at least one security.

During the transition, trading occurs on a deferred settlement basis under temporary ASX codes for both shares and listed options. Normal T+2 trading under the standard “ATH” code resumes on 12 June 2026, so the operational impact is limited to the defined trading window.

Key Figures

Share consolidation ratio: 1 for 50 Deferred trading window: 3–11 June 2026 Record date: 4 June 2026 +1 more

4 metrics

Share consolidation ratio 1 for 50 Consolidation of share capital approved at Extraordinary General Meeting

Deferred trading window 3–11 June 2026 Post-consolidation trading under temporary ASX code “ATHDA”

Record date 4 June 2026 Record date for post-consolidation holdings

Normal trading resumes 12 June 2026 T+2 settlement under ASX code “ATH”

Key Terms

share consolidation, deferred settlement basis, T+2 settlement basis, Phase 3 pivotal trial, +2 more

6 terms

share consolidation financial

"the consolidation of the Company’s share capital on a 1 for 50 basis is now being actioned"

Share consolidation is a process where a company reduces the total number of its shares by combining multiple existing shares into a smaller number of higher-value shares. This can make each share more expensive and potentially improve the company’s image. For investors, it often means their ownership remains the same, but the value of each share increases, which can influence how the stock is perceived and traded.

deferred settlement basis financial

"trading in the Company’s securities takes place on a post-consolidation and deferred settlement basis"

A deferred settlement basis means payment and/or delivery for a securities transaction are scheduled for a later date than usual, so ownership and cash transfer occur after the trade is announced. For investors this changes when money is due, when they legally own the shares, and who bears price or settlement risk in the interim — like agreeing to buy a car now but paying and picking it up a week later, with any price or condition changes in between affecting each party.

T+2 settlement basis financial

"Normal trading (on a T+2 settlement basis) commences 12 June under ASX code “ATH”"

Phase 3 pivotal trial medical

"Alterity is preparing to initiate a Phase 3 pivotal trial in MSA"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

randomized, double-blind, placebo-controlled Phase 2 clinical trial medical

"ATH434 ... has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial"

Multiple System Atrophy (MSA) medical

"developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders"

A progressive neurological disorder in which brain cells that control movement, balance and automatic body functions (like blood pressure, bladder control and digestion) gradually fail, causing symptoms such as poor coordination, stiffness, fainting and urinary problems. Investors care because the condition drives demand for diagnostic tests, therapies and long-term care solutions; successful clinical trials, regulatory approvals or setbacks can materially affect the valuation and revenue prospects of companies developing treatments, devices or related services.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alterity Therapeutics (ATHE) announce in this Form 6-K?

Alterity Therapeutics announced it is implementing a 1 for 50 consolidation of its share capital, following shareholder approval. The move adjusts both the number of shares held and the share price, with fractional entitlements rounded up to at least one security per shareholder.

What is the share consolidation ratio for Alterity Therapeutics (ATHE)?

Alterity Therapeutics is consolidating its shares on a 1 for 50 basis. For every 50 existing shares, investors will now hold one consolidated share, with any fractional entitlements rounded up to the nearest whole security to ensure each holder keeps at least one share.

When will Alterity Therapeutics shares trade under the temporary ASX code ATHDA?

Alterity shares trade under the temporary ASX code “ATHDA” from 3 June 2026 until the close of trading on 11 June 2026. During this period, trading occurs on a post-consolidation, deferred settlement basis before normal T+2 trading resumes under the usual “ATH” code.

How are Alterity Therapeutics options affected by the share consolidation?

Alterity’s listed options “ATHO” and “ATHOA” will trade under temporary ASX codes “ATHDB” and “ATHDC” on a deferred settlement basis. This temporary change runs alongside the post-consolidation trading period for the shares, aligning option trading mechanics with the consolidated capital structure.

When does normal trading resume for Alterity Therapeutics (ATHE) on the ASX?

Normal T+2 settlement trading for Alterity shares resumes on 12 June 2026 under the standard ASX code “ATH”. Before that date, from 3 June to 11 June 2026, trading occurs on a post-consolidation, deferred settlement basis under the temporary code “ATHDA”.

How does the share consolidation impact Alterity Therapeutics shareholders?

Shareholders now hold fewer Alterity shares due to the 1 for 50 consolidation, while the share price has adjusted accordingly. Any fractional entitlements are rounded up to the nearest whole number, ensuring each shareholder retains at least one security after the consolidation is completed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 08:50 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Share Consolidation Effective, Trading Under ATHDA

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: June 4, 2026

2

Exhibit 99.1

Share Consolidation and ASX Code

‒ Alterity shares to trade under the temporary ticker of “ATHDA” until 12 June ‒

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 June 2026:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, advises that, further to shareholder approval received at the Extraordinary General Meeting on 29 May, 2026, the consolidation of the Company’s share capital on a 1 for 50 basis is now being actioned.

From 3 June 2026 until the close of trading on 11 June 2026, trading in the Company’s securities takes place on a post-consolidation and deferred settlement basis under a temporary ASX code “ATHDA”, with a record date of 4 June 2026.

Additionally, the Company’s “ATHO” and “ATHOA” listed options will trade under temporary codes “ATHDB” and “ATHDC” respectively on a deferred settlement basis.

Normal trading (on a T+2 settlement basis) commences 12 June under ASX code “ATH”.

Shareholders are reminded that the number of shares they hold has been reduced in accordance with the 1 for 50 consolidation ratio, with any fractional entitlements rounded up to the nearest whole number (to a minimum of 1 security).  The Company’s share price has adjusted accordingly.

For more information, please refer to the Company’s ASX Announcements on Consolidation and Notice of General Meeting released to the ASX.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytx.com.

Authorization & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors

Elyse Shapiro

ir@alteritytx.com

Remy Bernarda

Investor Relations Advisory Solutions

ir@alteritytx.com

+1 (415) 203-6386

Media

Casey McDonald

Tiberend Strategic Advisors, Inc.

cmcdonald@tiberend.com

+1 (646) 577-8520

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 9.0 KB